Supplemental Material

Similar documents
Extend and pre-amplify 92 unique DNA reporter sequences by proximity extension.

Data Package. Multiplex Oncology I 96 96

DATA PACKAGE. Multiplex CVD I 96 96

Cytokines, adhesion molecules and apoptosis markers. A comprehensive product line for human and veterinary ELISAs

Supplementary Table 1. Genes analysed for expression by angiogenesis gene-array.

Effects of Ole e 1 allergen on human bronchial epithelial cells cultured at air-liquid interface (No. JIACI-D )

FirePlex Multiplex Immunoassay product list

TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b NF-kB pathway cluster, Enrichment Score: 3.57

Supplementary Online Content

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

Growth Factors. BIT 230 Walsh Chapter 7

ELISA kits for Cancer

Supplementary Table S1. Primers used for quantitative real-time polymerase chain reaction. Marker Sequence (5 3 ) Accession No.

Cytokines. Luděk Šefc. Cytokines Protein regulators of cellular communication. Cytokines x hormones

The Role of Microenvironment in the Control of Tumor Angiogenesis

Effects of cigarette smoking on cardiovascularrelated protein profiles in two community-based cohort studies

* Kyoto Encyclopedia of Genes and Genomes.

Supplemental Figure Legends

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION

Proseek Multiplex Inflammation I 96 96

Additional file 2 List of pathway from PID

Circulating Levels of Inflammatory Proteins and Survival in Patients with

basic Fibroblast Growth Factor 2 (FGF-b; Sf9 insect cell-derived), rhuman

Assessing Changes In Biomarkers Of Effect In Smokers Who Switch To A Closed System Electronic Cigarette. Liz Mason Kunming, China 26 th October 2018

Supplementary Figure 1: Func8onal Network Analysis of Kinases Significantly Modulated by MERS CoV Infec8on and Conserved Across All Time Points

ProcartaPlex multiplex immunoassays for the Luminex platform

Table S1 Differentially expressed genes showing > 2 fold changes and p <0.01 for 0.01 mm NS-398, 0.1mM ibuprofen and COX-2 RNAi.

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

Multiplexed immunoassay-based serum cytokine profiling for potential prognosis predictors in patients with metastatic breast cancer

Electrolytes. Summary: (This area will include a brief description of what the protocol is used for and why someone would need to use it.

Dilution Factor Serum Plasma Urine CSF (Other)

CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS Emerging Assays, and Companies Developing New Technologies and Products.

Immunology lecture: 14. Cytokines: Main source: Fibroblast, but actually it can be produced by other types of cells

Genetics and Cancer Ch 20

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

MCP uL 25uL 25uL 25uL Typical Dilution 1:2 None None None Manufacturer Defined Minimum Detectible Concentration

T cell and Cell-mediated immunity

T cell-mediated immunity

Biomarker Discovery: Prognosis and Management of Chronic Diabetic Foot Ulcers

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications

Tumor Associated Macrophages as a Novel Target for Cancer Therapy

Generation of post-germinal centre myeloma plasma B cell.

SUPPLEMENTARY DATA Expression of complement factors is induced in DBA/2 mice following administration of C. albicans

Tyrosine kinases. Cell surface receptors ligand binding. Producer cell RNA. Target cell

Supplementary Figure 1

Basis of Immunology and

Physicochemical Properties Can Be Key Determinants of Mesoporous Silica Nanoparticle Potency In Vitro

Supplementary Table SI: Y strain T. cruzi infection results in the upregulation of 381 genes at the site of infection.

Targeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018

Subject Index. Bcl-2, apoptosis regulation Bone marrow, polymorphonuclear neutrophil release 24, 26

Chapter 11 CYTOKINES

AUTOANTIBODY SYSTEM. Detect Quantify Classify PROFILING. ITSI Biosciences LLC 633 Napoleon Street Johnstown, PA 15901, USA.

Adaptive Immunity. Jeffrey K. Actor, Ph.D. MSB 2.214,

Tumor Microenvironment and Immune Suppression

Cytokine Profiling in Human Colostrum and Milk by Protein Array

C M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.

To compare the relative amount of of selected gene expression between sham and

SUPPLEMENTARY FIG. S2. b-galactosidase staining of

VALIDATION DATA. Multiplex CVD II 96 96

Time course of immune response

Speciality and Research Controls

ProcartaPlex Multiplex Immunoassays

are associated with sickle cell disease and carriers: a study of patients from the southeastregion of Iran

B-cell. Astrocyte SCI SCI. T-cell

Cell-Derived Inflammatory Mediators

T cell and Cell-mediated immunity

T cells III: Cytotoxic T lymphocytes and natural killer cells

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression

Seeds and soil theory by Stephen Paget at the end of the XIX century.

Test Bank for Basic Immunology Functions and Disorders of the Immune System 4th Edition by Abbas

Immunologic messenger molecules: Cytokines, interferons, and chemokines

CYTOKINES. Based on: Cellular and Molecular Immunology, 4 th ed.,abbas A.K., Lichtman A.H. and Pober J.S. Sounders company; Philadelphia, 2010.

Allergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis

Regulating the Regulators for Cancer Immunotherapy: LAG-3 Finally Catches Up. Drew Pardoll Sidney Kimmel Cancer Center Johns Hopkins

A. Incorrect! It s not correct. Synergism of cytokines refers to two or more cytokines acting together.

CO 2 tolerance of Atlantic salmon post-smolts in recirculating aquaculture systems

Virchow s Hypothesis lymphorecticular infiltration of cancer reflected the origin of cancer at sites of inflammation

Expression levels of b-pix mrna in ALS-MSCs and C-MSCs.

Index. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type.

Lectins: selected topics 3/2/17

2. Cytokines and chemokines

Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer

Immunology Research Related Cytokine Products

DNA vaccine, peripheral T-cell tolerance modulation 185

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

Late regulation of immune genes and micrornas in circulating leukocytes in a pig model of

Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell?

SUPPLEMENTAL TABLE I. Identified Proteins in Bovine Testicular Hyaluronidase Type I-S via LC-MS/MS

Supporting Information

The T cell receptor for MHC-associated peptide antigens

Nori Rabbit IL-2 ELISA Kit DataSheet

MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism

Rho GTPase activating protein 8 /// PRR5- ARHGAP8 fusion

Darwinian selection and Newtonian physics wrapped up in systems biology

remember that T-cell signal determine what antibody to be produce class switching somatical hypermutation all takes place after interaction with

T cell maturation. T-cell Maturation. What allows T cell maturation?

Molecular Cell Biology - Problem Drill 19: Cell Signaling Pathways and Gene Expression

Innate Immunity II. Integration. Lindsay Nicholson Advanced Immunology L2

The Hallmarks of Cancer

Transcription:

Supplemental Material The metabolic syndrome, inflammation and colorectal cancer risk; an evaluation of large panels of plasma protein markers using repeated, prediagnostic samples Sophia Harlid, Robin Myte, Bethany Van Guelpen Table of Contents: Page Figure S (MetS and its components per individual over time) Figure S (Levels of MetS associated proteins (log) per individual over time) Figure S (Direction of protein-mets associations) 4 Figure S4 (Protein-protein associations of MetS associated proteins) Table S (Proteins included in Proseek Multiplex immunoassay panels) -

MetS, ICC:.4 BMI, ICC:.8 Triglycerides, ICC:. 4 Sex mid BP, ICC:.44 Blood glucose, ICC: Total cholsterol, ICC:. Men Women Change decrease increase 7 8 Age Figure S. Metabolic syndrome (MetS) and its components in the study participants over time. ICC: Intraclass correlation coefficient, i.e., proportion of total variance due to variation between individuals.

4.... FURIN HGF TNFSF4 FGF 8. 7. 4 7.. 7.... ERBB IL TNFSF OPG 4. 8. 7. FGF BP ESM SEZL SCF Sampling time point Sex Men Women. 8. 8.. 4.8. 8. 8. 4 7. 4.4 7. MetS Figure S. Direction of protein-metabolic syndrome (MetS) associations. Protein levels (log) plotted against MetS score, and regression lines with error bounds plotted without random intercepts for simplicity. The proteins are sorted according to size and direction of regression coefficient.

SEZL, ICC:.7 TNFSF, ICC:. FGF BP, ICC:. OPG, ICC:.8 ESM, ICC:.8 FURIN, ICC:.4 ERBB, ICC:. HGF, ICC:.4 Protein levels (log) Sampling time point Sex Men Women SCF, ICC:. FGF, ICC:.47 IL, ICC:.4 TNFSF4, ICC:. Participants Figure S. Levels of metabolic syndrome (MetS) associated proteins (log) per participant by sampling time point. The proteins are sorted according to ICC (ICC: Intra-class correlation coefficient, i.e., proportion of total variance due to variation between individuals.) 4

SCF SCF OPG ERBB SEZL ESM FGF BP.. HGF TNFSF4 FURIN IL FGF..... TNFSF OPG..4.4..4.8 ERBB......4.4. SEZL.4..4 4......4.4 ESM.4....8.. FGF BP HGF..4. 4........8.4.4.... TNFSF4......4 8..8 FURIN..4..8..4 8...4 IL.....8..7.8. FGF..4.......7.8 TNFSF..4.4...8.8 Figure S4. Partial correlations between metabolic syndrome (MetS) -associated proteins. Partial correlations were calculated by estimating Spearman s correlations on the standardized residuals from protein mixed models adjusting for age, sex, MetS, physical activity, smoking and education level. The black squares represent the two major clusters from a hierarchical cluster analysis on the correlations (using Euclidean distance with average linkage).

Table S. Proteins included in Proseek Multiplex immunoassay panels Protein UniProt No Immunoassay panel Comment Hepatocyte growth factor (HGF) P Both Interleukin- (IL-) P Both Stem cell factor (SCF) P8 Both Excluded from one panel TNF-related apoptosis-inducing ligand (TRAIL) P Both Excluded from one panel Transforming growth factor alpha (TGF-alpha) P Both Vascular endothelial growth factor A (VEGF-A) P Both Adenosine Deaminase (ADA) P8 Inflammation Artemin (ARTN) QT4W7 Inflammation Excluded (>% missing) Axin- (AXIN) O Inflammation Beta-nerve growth factor (Beta-NGF) P8 P8 Inflammation Brain-derived neurotrophic factor (BDNF) P Inflammation Caspase 8 (CASP-8 ) Q47 Inflammation C-C motif chemokine (CCL) Q7 Inflammation C-C motif chemokine (CCL) P78 Inflammation C-C motif chemokine (CCL) P77 Inflammation C-C motif chemokine (CCL) O444 Inflammation C-C motif chemokine 8 (CCL8) QNRJ Inflammation C-C motif chemokine 4 (CCL4 ) P Inflammation CDL receptor (CD) P4 Inflammation CUB domain-containing protein (CDCP) QHV8 Inflammation C-X-C motif chemokine (CXCL) P4 Inflammation C-X-C motif chemokine (CXCL) P778 Inflammation C-X-C motif chemokine (CXCL) O4 Inflammation C-X-C motif chemokine (CXCL) P48 Inflammation C-X-C motif chemokine (CXCL) P8 Inflammation C-X-C motif chemokine (CXCL ) Q7 Inflammation Cystatin D (CST) P8 Inflammation Delta and Notch-like epidermal growth factor-related recep (DNER) Q8NFT8 Inflammation Eotaxin- (CCL) P7 Inflammation Eukaryotic translation initiation factor 4E-binding protein (4E-BP) Q4 Inflammation Fibroblast growth factor (FGF-) O7 Inflammation Fibroblast growth factor (FGF-) QNSA Inflammation Fibroblast growth factor (FGF-) QGZV Inflammation Fibroblast growth factor (FGF-) Q8NF Inflammation Fms-related tyrosine kinase ligand (FltL) P477 Inflammation Fractalkine (CXCL ) P784 Inflammation Glial cell line-derived neurotrophic factor (hgdnf) P Inflammation Table continues on next page

Table S. Cont. Protein UniProt No Immunoassay panel Comment Interferon gamma (IFN-gamma) P7 Inflammation Interleukin- alpha (IL- alpha) P8 Inflammation Excluded (>% missing) Interleukin- (IL-) P Inflammation Interleukin- receptor subunit alpha (IL-RA) Q Inflammation Excluded (>% missing) Interleukin- receptor subunit beta (IL-RB) Q84 Inflammation Interleukin- subunit beta (IL-B) P4 Inflammation Interleukin- (IL-) P Inflammation Excluded (>% missing) Interleukin- receptor subunit alpha (IL-RA) Q Inflammation Interleukin-7A (IL-7A) Q Inflammation Interleukin-7C (IL-7C) QPM4 Inflammation Interleukin-8 (IL-8) Q4 Inflammation Interleukin-8 receptor (IL-8R) Q478 Inflammation Interleukin- (IL-) P8 Inflammation Excluded (>% missing) Interleukin- receptor subunit beta (IL-RB) P4784 Inflammation Excluded (>% missing) Interleukin- (IL-) QNYY Inflammation Excluded (>% missing) Interleukin- receptor subunit alpha (IL-RA) QUHF4 Inflammation Excluded (>% missing) Interleukin- receptor subunit alpha- (IL- RA) Q8NP7 Inflammation Excluded (>% missing) Interleukin-4 (IL-4) Q7 Inflammation Excluded (>% missing) Interleukin- (IL-) O7 Inflammation Excluded (>% missing) Interleukin-4 (IL-4) P Inflammation Excluded (>% missing) Interleukin- (IL-) P Inflammation Excluded (>% missing) Interleukin-7 (IL-7) P Inflammation Interleukin-8 (IL-8) P4 Inflammation Latency-associated peptide transforming growth factor beta (LAP TGFbeta-) P7 Inflammation Leukemia inhibitory factor (LIF) P8 Inflammation Excluded (>% missing) Leukemia inhibitory factor receptor (LIF-R) P47 Inflammation Macrophage colony-stimulating factor (CSF-) P Inflammation Macrophage inflammatory protein -alpha (MIP- alpha ) P47 Inflammation Excluded (>% missing) Matrix metalloproteinase- (MMP-) P Inflammation Matrix metalloproteinase- (MMP-) P8 Inflammation Monocyte chemotactic protein (MCP-) P Inflammation Monocyte chemotactic protein (MCP-) P87 Inflammation Monocyte chemotactic protein (MCP-) P88 Inflammation Monocyte chemotactic protein 4 (MCP-4) Q Inflammation Natural killer cell receptor B4 (CD44) QBZW8 Inflammation Neurotrophin- (NT-) P78 Inflammation Neurturin (NRTN) Q748 Inflammation Excluded (>% missing) Table continues on next page 7

Table S. Cont. Protein UniProt No Immunoassay panel Comment Oncostatin-M (OSM) P7 Inflammation Osteoprotegerin (OPG) O Inflammation Programmed cell death ligand (PD-L) QNZQ7 Inflammation Protein S-A (EN-RAGE ) P8 Inflammation Signaling lymphocytic activation molecule (SLAMF) Q Inflammation SIR-like protein (SIRT) Q8IXJ Inflammation STAM-binding protein (STAMPB) O Inflammation Sulfotransferase A (STA) P Inflammation T cell surface glycoprotein CD isoform (CD) Q8WWJ7 Inflammation T-cell surface glycoprotein CD (CD) P7 Inflammation Thymic stromal lymphopoietin (TSLP) QD Inflammation Excluded (>% missing) TNF-beta (TNFB) P74 Inflammation TNF-related activation-induced cytokine (TRANCE) O4788 Inflammation Tumor necrosis factor (Ligand) superfamily, member (TWEAK) Q4ACW Inflammation Tumor necrosis factor (TNF) P7 Inflammation Excluded (>% missing) Tumor necrosis factor ligand superfamily member 4 (TNFSF4) O47 Inflammation Tumor necrosis factor receptor superfamily member (TNFRSF) Q7 Inflammation Urokinase-type plasminogen activator (upa) P74 Inflammation '-nucleotidase ('-NT) P8 Oncology II A disintegrin and metalloproteinase with thrombospondin motifs (ADAM-TS ) Q8TE8 Oncology II A/B (MIC-A/B) Q8 Oncology II AlPha-taxilin (TXLNA) P Oncology II AmPhiregulin (AR) P4 Oncology II Annexin A (ANXA) P8 Oncology II Carbonic anhydrase (CA) Q7 Oncology II Carboxypeptidase E (CPE) P87 Oncology II Carcinoembryonic antigen-related celladhesion molecule (CEACAM) P88 Oncology II Carcinoembryonic antigen-related celladhesion molecule (CEACAM) P7 Oncology II Cathepsin L (CTSV) O Oncology II CD antigen (CD) O7 Oncology II CD7 antigen (CD7) P84 Oncology II CD48 antigen (CD48) P Oncology II CD7 antigen (CD7) P7 Oncology II Cornulin (CRNN) QUBG Oncology II C-type lectin domain family 4 member K(CD7) QUJ7 Oncology II C-X-C motif chemokine (CXCL) O47 Oncology II Cyclin-dependent kinase inhibitor (CDKNA) P8 Oncology II Excluded (>% missing) Table continues on next page 8

Table S. Cont. Protein UniProt No Immunoassay panel Comment Delta-like protein (DLL) O48 Oncology II Disintegrin and metalloproteinase domain-containing protein (ADAM8) P78 Oncology II Endothelial cell-specific molecule (ESM-) QNQ Oncology II EPhrin type-a receptor (EPH) P7 Oncology II FAS-associated death domain protein (FADD) Q8 Oncology II Fc receptor-like B (FCRLB) QBAA4 Oncology II Fibroblast growth factor-binding Protein (FGF-BP) Q4 Oncology II Folate receptor alpha (FR-alpha) P8 Oncology II Folate receptor gamma (FR-gamma) P44 Oncology II Furin (FURIN) P8 Oncology II Galectin- (Gal-) P8 Oncology II Glypican- (GPC) P Oncology II Granzyme B (GZMB) P44 Oncology II Granzyme H (GZMH) P78 Oncology II ICOS ligand (ICOSLG) O744 Oncology II Insulin-like growth factor receptor (IGFR) P8 Oncology II Excluded (>% missing) Integrin alpha-v (ITGAV) P7 Oncology II Integrin beta- (ITGB) P884 Oncology II Interferon gamma receptor (IFN-gamma-R) P Oncology II Kallikrein- (hk) QUBX7 Oncology II Kallikrein- (KLK) QUKR Oncology II Kallikrein-4 (hk4) QPG Oncology II Kallikrein-8 (hk8) O Oncology II Ly/PLAUR domain-containing Protein (LYPD) O74 Oncology II Melanoma-derived growth regulatory Protein (MIA) Q74 Oncology II Mesothelin (MSLN) Q4 Oncology II Methionine aminopeptidase (MetAp) P7 Oncology II MHC class I Polypeptide-related se Quence Q8 Oncology II Excluded (>% missing) Midkine (Mk) P74 Oncology II Mothers against decapentaplegic homolog (MAD homolog ) Q77 Oncology II Mucin- (MUC-) Q8WXI7 Oncology II Nectin-4 (PVRL4) QNY8 Oncology II Pancreatic prohormone (PPY) P8 Oncology II Podocalyxin (PODXL) O Oncology II Pro-epidermal growth factor (EGF) P Oncology II Protein CYR (CYR) O Oncology II Protein S-A (SA) P4 Oncology II Table continues on next page

Table S. Cont. Protein UniProt No Immunoassay panel Comment Protein S-A4 (SA4) P447 Oncology II Proto-oncogene tyrosine-protein kinasereceptor Ret (RET) P74 Oncology II Receptor tyrosineprotein kinase erbb-(erbb) P4 Oncology II Receptor tyrosineprotein kinase erbb- (ERBB) P8 Oncology II Receptor tyrosineprotein kinase erbb-4 (ERBB4) Q Oncology II R-spondin- (RSPO) QBXY4 Oncology II Secretory carrier-associated membraneprotein (SCAMP) O488 Oncology II Seizure -like protein (SEZL) QBYH Oncology II SPARC (SPARC) P48 Oncology II Syndecan- (SYND) P887 Oncology II T-cell leukemia / lymphoma Protein A (TCLA) P7 Oncology II TGF-beta receptor type- (TGFR-) P77 Oncology II Tissue factor pathway inhibitor (TFP-) P487 Oncology II T-lymphocyte surface antigen Ly- (LY) QHBG7 Oncology II Toll-like receptor (TLR) O4 Oncology II Transmembrane glycoprotein NMB (GPNMB) Q4 Oncology II Tumor necrosis factor ligand superfamilymember (TNFSF) O7888 Oncology II Tumor necrosis factor ligand superfamilymember (FASLG) P48 Oncology II Tumor necrosis factor receptor superfamilymember (TNFRSF) QNS8 Oncology II Tumor necrosis factor receptor superfamilymember 4 (TNFRSF4) P448 Oncology II Tumor necrosis factor receptor superfamilymember B (TNFRSFB) O7 Oncology II Tyrosineprotein kinase ABL (ABL) P Oncology II Tyrosineprotein kinase Lyn (LYN) P748 Oncology II Vascular endothelial growth factor receptor (VEGFR-) P8 Oncology II Vascular endothelial growth factor receptor (VEGFR-) P Oncology II VEGF-co regulated chemokine (CXL7) QUXB Oncology II Vimentin (VIM) P87 Oncology II WAP four-disulfide core domain protein (WFDC) Q48 Oncology II Wnt inhibitory factor (WIF-) QYW Oncology II WNT-inducible-signaling pathway protein (WISP-) O88 Oncology II Xaa-pro aminopeptidase (XPNPEP) O48 Oncology II